MedPath

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: Elimusertib (BAY1895344)
Registration Number
NCT04095273
Lead Sponsor
Bayer
Brief Summary

The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab. In addition researchers want to find for patients the optimal dose of elimusertib in combination with pembrolizumab, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication, elimusertib, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Participant must be ≥18 years of age inclusive, at the time of signing the informed consent.
  • Presence of the putative biomarkers of DDR deficiency in tumor and/or other tissues (dose escalation only).
  • Participants must have histologically confirmed solid tumors .
  • Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1.
  • Adequate bone marrow function as assessed by laboratory tests to be conducted within 7 days before the first dose of study intervention.
  • Participants must have adequate kidney function, as assessed by the estimated glomerular filtration rate (eGFR) > 40 mL/min per 1.73 m*2 within 7 days before the first dose of study intervention.
  • Participants must have adequate liver function as assessed by laboratory tests to be conducted within 7 days before the first dose of study intervention.
  • Participants must have adequate coagulation, as assessed by laboratory tests as applicable, (to be conducted within 7 days before the first dose of study intervention) or be on stable anti-coagulation treatment.
  • Adequate cardiac function per institutional normal measured by echocardiography (recommended) or multigated acquisition (MUGA) scan/cardiac MRI per institutional guidelines.
  • Participants must have measurable disease (at least one measurable lesion) as per RECIST 1.1, or evaluable disease according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) classification as applicable. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
Exclusion Criteria
  • Ongoing infections of Common terminology criteria for adverse events (CTCAE) grade ≥2 not responding to therapy or active clinically serious infections.

  • Participants with

    • Known human immunodeficiency virus (HIV)
    • Active Hepatitis B infection (positive for Hepatitis B surface antigen (HBsAg)/ Hepatitis B virus (HBV) DNA).
    • Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay).
  • Active autoimmune disease (active defined as having autoimmune disease related symptoms and detectable autoantibodies) that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Diagnosis of immunodeficiency or participant is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.

  • Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade ≥ 2 dyspnea).

  • History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (angina symptoms at rest), new-onset angina (within the past 6 months before study entry), myocardial infarction within the past 6 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted)

  • Uncontrolled arterial hypertension despite optimal medical management (per investigator's opinion)

  • Moderate or severe hepatic impairment, i.e., Child-Pugh class B or C.

  • History of organ allograft transplantation

  • Evidence or history of bleeding disorder, i.e., any hemorrhage / bleeding event of CTCAE Grade > 2 within 4 weeks before the first dose of study intervention

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Dose expansion cohort 3a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 1a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 negative breast cancer (HER2-negative BC), known to be positive for Ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known microsatellite instability-high (MSI-H) cannot be included
Dose expansion cohort 3 of ElimusertibPembrolizumab (Keytruda®)Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 4 of ElimusertibPembrolizumab (Keytruda®)Participants with advanced Non-small cell lung cancer (NSCLC) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 4a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced NSCLC and without DDR deficiency alterations as described above. VUS of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 5 of ElimusertibPembrolizumab (Keytruda®)Participants with advanced pancreatic cancer, known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 5a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced pancreatic cancer and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
Dose expansion cohort 6a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced mCRPC and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
Dose escalation of ElimusertibPembrolizumab (Keytruda®)2 dose levels of Elimusertib are planned
Dose escalation of ElimusertibElimusertib (BAY1895344)2 dose levels of Elimusertib are planned
Dose expansion cohort 3 of ElimusertibElimusertib (BAY1895344)Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 4 of ElimusertibElimusertib (BAY1895344)Participants with advanced Non-small cell lung cancer (NSCLC) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 6 of ElimusertibPembrolizumab (Keytruda®)Participants with advanced Metastatic castration-resistant prostate cancer (mCRPC), known to be DDR deficiency biomarker positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 1b of ElimusertibPembrolizumab (Keytruda®)Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 2a of ElimusertibElimusertib (BAY1895344)Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 2b of ElimusertibPembrolizumab (Keytruda®)Participants with advanced CRC, known to be DDR deficiency biomarker -positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 3a of ElimusertibElimusertib (BAY1895344)Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 4a of ElimusertibElimusertib (BAY1895344)Participants with advanced NSCLC and without DDR deficiency alterations as described above. VUS of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
Dose expansion cohort 6a of ElimusertibElimusertib (BAY1895344)Participants with advanced mCRPC and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
Dose expansion cohort 1a of ElimusertibElimusertib (BAY1895344)Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 negative breast cancer (HER2-negative BC), known to be positive for Ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known microsatellite instability-high (MSI-H) cannot be included
Dose expansion cohort 5 of ElimusertibElimusertib (BAY1895344)Participants with advanced pancreatic cancer, known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 2a of ElimusertibPembrolizumab (Keytruda®)Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 2b of ElimusertibElimusertib (BAY1895344)Participants with advanced CRC, known to be DDR deficiency biomarker -positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 1b of ElimusertibElimusertib (BAY1895344)Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 6 of ElimusertibElimusertib (BAY1895344)Participants with advanced Metastatic castration-resistant prostate cancer (mCRPC), known to be DDR deficiency biomarker positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
Dose expansion cohort 5a of ElimusertibElimusertib (BAY1895344)Participants with advanced pancreatic cancer and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
Primary Outcome Measures
NameTimeMethod
Incidence of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)Up to 30 days after last study intervention administration
Frequency of Dose limiting toxicities (DLTs) at each dose level during dose escalation of BAY1895344Cycle 1 (21 days)
Severity of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)Up to 30 days after last study intervention administration
Recommended phase II dose (RP2D) of BAY1895344Up to 24 months

The RP2D will be determined in dose expansion part based on multiple parameters (i.e., safety, tolerability, PK, pharmacodynamics, efficacy) and will be a dose equal to or lower than the MTD (Maximum Tolerated Dose).

Secondary Outcome Measures
NameTimeMethod
Cmax,md of ElimusertibCycle 1 (21 days), Day 17 (dosing schedule 1) or Cycle 1 (21 days), Day 10 (dosing schedule 2)
AUC(0-12) of ElimusertibCycle 1 (21 days), Day 8 (dosing schedule 1) or Cycle 1 (21 days), Day 1 (dosing schedule 2)

If the main parameters AUC(0-12) cannot be calculated reliably, it might become necessary to appoint the additional parameters AUC(0-tlast) as secondary variables.

Incidence of partial response (PR)Up to 24 months

Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)

Incidence of progressive disease (PD)Up to 24 months

Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)

Objective Response Rate (ORR)Up to 24 months
Disease control rate (DCR)Up to 24 months
Cmax of ElimusertibCycle 1 (21 days), Day 8 (dosing schedule 1) or Cycle 1 (21 days), Day 1 (dosing schedule 2)
Incidence of stable disease (SD)Up to 24 months

Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)

AUC(0-12)md of ElimusertibCycle 1 (21 days), Day 17 (dosing schedule 1) or Cycle 1 (21 days), Day 10 (dosing schedule 2)

If the main parameters AUC(0-12)md cannot be calculated reliably, it might become necessary to appoint the additional parameters AUC(0-tlast)md as secondary variables.

Incidence of Complete response (CR)Up to 24 months

Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)

Trial Locations

Locations (16)

Stanford University

🇺🇸

Palo Alto, California, United States

Yale Cancer Center

🇺🇸

New Haven, Connecticut, United States

Johns Hopkins Hospital/Health System

🇺🇸

Baltimore, Maryland, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Ohio State University

🇺🇸

Columbus, Ohio, United States

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Baden-Württemberg, Germany

Fundacion Jimenez Diaz (Clinica de la Concepcion)

🇪🇸

Madrid, Spain

Kantonsspital St. Gallen

🇨🇭

St. Gallen, Sankt Gallen, Switzerland

Freeman Hospital

🇬🇧

Newcastle, Tyne And Wear, United Kingdom

Royal Marsden NHS Trust (Surrey)

🇬🇧

Sutton, Surrey, United Kingdom

Ospedale Regionale di Bellinzona e Valli

🇨🇭

Bellinzona, Ticino, Switzerland

Eberhard-Karls-Universität Tübingen

🇩🇪

Tübingen, Baden-Württemberg, Germany

Weill Cornell Medical College

🇺🇸

New York, New York, United States

Hospital Madrid Norte Sanchinarro

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath